The Experts below are selected from a list of 1589850 Experts worldwide ranked by ideXlab platform
Liu Ting - One of the best experts on this subject based on the ideXlab platform.
The Chemotherapy of subcutaneous implantable pump system and the combined treatment of oral squamous cell carcinomasJournal of Modern Oncology, 2007Co-Authors: Liu TingAbstract:
Objective:To investigate the effect of Chemotherapy of the subcutaneous implantable pump system(SIPS)and its value in the combined treatment of oral squamous cell carcinomas. Methods: The SIPS was employed in the Chemotherapy through the external carotid artery for 29 patients with oral squamous cell carcinomas.The response was assessed. The effect of SIPS Chemotherapy in combination with operation and radiotherapy was evaluated. Results: The overall effective rate after SIPS Chemotherapy was 87.5% .No obvious side effects were observed .The procedure of SIPS was simple alowed a long period for use. Conclusion: The SIPS is one of the best ways to perform Chemotherapy for oral squamous cell carcinomas. It is valuable for single Chemotherapy with multiple drugs and cycles, for assistant Chemotherapy before and after operation ,and for Chemotherapy combined with radiotherapy.
Oluf Dimitri Røe - One of the best experts on this subject based on the ideXlab platform.
Epigenetic predictive biomarkers for response or outcome to platinum-based Chemotherapy in non-small cell lung cancer, current state-of-artThe Pharmacogenomics Journal, 2019Co-Authors: Weronika Maria Szejniuk, Ana I. Robles, Tine Mcculloch, Ursula Gerda Inge Falkmer, Oluf Dimitri RøeAbstract:
Platinum-based Chemotherapy is commonly used to treat non-small cell lung cancer (NSCLC). However, its efficacy is limited and no molecular biomarkers that predict response are available. In this review, we summarize current knowledge concerning potential epigenetic predictive markers for platinum-based Chemotherapy response in NSCLC. A systematic search of PubMed and ClinicalTrials.gov using keywords “non-small cell lung cancer” combined with “Chemotherapy predictive biomarkers”, “Chemotherapy epigenetics biomarkers”, “Chemotherapy microRNA biomarkers”, “Chemotherapy DNA methylation” and “Chemotherapy miRNA biomarkers” revealed 1740 articles from PubMed and 36 clinical trials. Finally, 22 papers and no trials fulfilled the review criteria. Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based Chemotherapy in advanced NSCLC. RASSF1A methylation measured in tumor or blood was predictive for response to neoadjuvant Chemotherapy. These biomarkers remain experimental and none have been tested in a prospective trial.
Enriqueta Felip - One of the best experts on this subject based on the ideXlab platform.
phase iii randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive stage small cell lung cancerJournal of Clinical Oncology, 2016Co-Authors: Martin Reck, A Luft, Aleksandra Szczesna, Libor Havel, Sang We Kim, Wallace Akerley, Maria Catherine Pietanza, Christoph C Zielinski, Michael Thomas, Enriqueta FelipAbstract:
Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line Chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods Patients were randomly assigned at a ratio of one to one to receive Chemotherapy with etoposide and platinum (cisplatin or carboplatin) plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of four doses each in a phased induction schedule (Chemotherapy in cycles one to four; ipilimumab or placebo beginning in cycle three up to cycle six), followed by ipilimumab or placebo maintenance every 12 weeks. Primary end point was overall survival (OS) among patients receiving at least one dose of blinded study therapy. Results Of 1,132 patients randomly assigned, 954 received at least one dose of study therapy (Chemotherapy plus ipilimumab, n = 478; Chemotherapy plus placebo, n = 476). Median OS was 11.0 months for Chemotherapy plus ipilimumab versus 10.9 months for Chemotherapy plus placebo (hazard ratio, 0.94; 95% CI, 0.81 to 1.09; P = .3775). Median progression-free survival was 4.6 months for Chemotherapy plus ipilimumab versus 4.4 months for Chemotherapy plus placebo (hazard ratio, 0.85; 95% CI, 0.75 to 0.97). Rates and severity of treatment-related adverse events were similar between arms, except for diarrhea, rash, and colitis, which were more frequent with Chemotherapy plus ipilimumab. Rate of treatment-related discontinuation was higher with Chemotherapy plus ipilimumab (18% v 2% with Chemotherapy plus placebo). Five treatment-related deaths occurred with Chemotherapy plus ipilimumab and two with Chemotherapy plus placebo. Conclusion Addition of ipilimumab to Chemotherapy did not prolong OS versus Chemotherapy alone in patients with newly diagnosed extensive-stage disease SCLC. No new or unexpected adverse events were observed with Chemotherapy plus ipilimumab. Several ongoing studies are evaluating ipilimumab in combination with programmed death-1 inhibitors in SCLC.
Emine Ozgur Unlu - One of the best experts on this subject based on the ideXlab platform.
Journal of Clinical Oncology, 2013Co-Authors: Serap Hasturk, Ozlem Olgunus, Abdullah Tuli, Ebru Dundar, Emine Ozgur UnluAbstract:
e19071 Background: Non small cell lung cancer is the most common cause of death due to cancer in the world. The role of ERCC1 and RRM1 genes has been researched in prediction of lung cancer prognosis and response of patients to chemotheraphy. We aimed to evaluate the effects of ERCC1 and RRM1 gene expressions profiles on the prediction of the prognosis and the treatment on bronchoscopy specimens of advanced stage NSCLC patients. Methods: The levels of ERCC1 and RRM1 gene expressions were studied for 76 patients which were diagnosed by bronchoscopic biopsy parafin embedded tissue samples. The RRM1 and ERCC1 gene expression profiles were examined by RT-PCR method. Forty were diagnosed with squamous cell cancer, 24 with adenocarcinoma, 12 with NOS NSCLC. Thirty patients were Chemotherapy native, 33 were received gemcitabine-cisplatin and 13 were received docetaxel- cisplatin doublets Chemotherapy. Results: The mean age of the patients in the study was 59.8±9.3 (years ± SD). The levels of gene expressions of ERCC1 and RRM1 were found to be 2-9 (median 4.9), and 1.3-17.7 (median 6.8). No significant difference was detected between ERCC1 and RRM1 levels and age, gender, histologic type, ECOG, weight loss when the median gene expression levels were used as cut off value. Also, no significant difference was observed for survival analysis among the patients that have low ERCC1 mRNA level (p=0.41). The level of gene expression of ERCC1 was lower in patients with advanced stage (p=0.06). In addition, no significant difference was detected for the survival analysis within the patients that have the low and high RRM1 mRNA levels (p=0.43). When the survival analyses were evaluated between the patients who had Chemotherapy and the ones who did not; no significant difference was detected according to ERCC1 and RRM1 levels. Conclusions: We conclude that the analysis of ERCC1 and RRM1 gene expression profiles based on bronchoscopy obtained samples appeares feasible, but the methodology and cut off points that was used to classify expression level as ‘high’ or ‘low’ would require further optimization. These two gene signature proposed for advanced stage NSCLC may not be useful, particularly not ready for clinical application.
Vivien H.c. Bramwell - One of the best experts on this subject based on the ideXlab platform.
Critical Reviews in Oncology Hematology, 1995Co-Authors: Vivien H.c. BramwellAbstract:
3.7. Non-randomizedstudies. 3.1.1. Intravenous Chemotherapy. 3.1.2. Intra-arterial Chemotherapy. Randomized studies 3.2.1. Chemotherapy versus control. 3.2.2. Studies evaluating the role of HDMTX. 3.2.3. Miscellaneous studies. Dose intensity of Chemotherapy Effect of Chemotherapy on pattern of metastases. Chemotherapy for tumors in axial sites. 3.5.1. Skull (including jaw). 3.5.2. Pelvis and spine. Chemotherapy for unusual variants of osteosarcoma. 3.6.1. Telangiectatic OS. Toxicity of Chemotherapy.